<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[LintonPharm Co., Ltd. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=39316></link><description><![CDATA[LintonPharm Co., Ltd. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Thu, 14 May 2026 03:06:42 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2021/12/12_3554238800_20211202105821_6480151684.gif]]></url></image><language>ko-KR</language><item><title><![CDATA[LintonPharm to Release Data on Catumaxomab for Advanced Gastric Cancer with Peritoneal Metastasis at 2022 ASCO Annual Meeting]]></title><link>https://www.newswire.co.kr/newsRead.php?no=945306</link><description><![CDATA[GUANGZHOU, China--(Business Wire/Korea Newswire)--LintonPharm Co., Ltd., a China-based biopharmaceutical company focusing on the development of T cell engaging bispecific antibodies for cancer immunotherapy, announces that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) An...]]></description><pubDate>Mon, 30 May 2022 09:10:00 +0900</pubDate></item><item><title><![CDATA[LintonPharm Announces First Patient Dosed in Phase 1 Clinical Trial of Catumaxomab for Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin]]></title><link>https://www.newswire.co.kr/newsRead.php?no=935637</link><description><![CDATA[GUANGZHOU, China--(Business Wire/Korea Newswire)--LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that the first patient has been dosed in the Company’s Phase 1/2 clinical trial program for catumaxomab (clinicaltrials.gov: NCT04799847), a monoclonal bispeci...]]></description><pubDate>Thu, 02 Dec 2021 11:35:00 +0900</pubDate></item><item><title><![CDATA[린톤팜, BCG 치료에 반응없는 비근육 침습성 방광암에 대한 카투막소맙 제1상 임상 시험에서 피실험자 대상 약물 첫 투여]]></title><link>https://www.newswire.co.kr/newsRead.php?no=935638</link><description><![CDATA[광저우, 중국--(Business Wire/뉴스와이어)--T 세포 관여 이중특이성 항체 개발에 주력하는 중국의 임상 단계 바이오 제약 회사 린톤팜(LintonPharm Co., Ltd.)이 카투막소맙에 대한 자사 1/2상 임상 시험 프로그램에서 환자에게 약물을 처음으로 투여했다고 1일 발표했다(clinicaltrials.gov: NCT04799847).  카투막소맙은 BCG(Bacillus Calmette-Guerin)에 반응하지 않는 비근육 침습성 방광암(NMIBC) 환자 치료 용도...]]></description><pubDate>Thu, 02 Dec 2021 11:35:00 +0900</pubDate></item></channel></rss>